Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ease of use and acceptability of Norditropin NordiFlex in children receiving growth hormone therapy
2009-017387-16Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Norditropine SimpleXx in growth hormone deficiency (GHD) and Short Stature (SS), sponsored by Novo Nordisk. Primary endpoint: Ease or difficulty of growth hormone injection using Norditropin NordiFlex. Started Feb 2010; status: completed.
02
Drugs
Norditropine SimpleXx
03
Conditions
growth hormone deficiency (GHD)Short Stature (SS)
Beyond the preview
Go deeper on 2009-017387-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017387-16.